Ligand News and Research

RSS

Study is the first to show that there are mechanisms in place for the immune system to identify cancer cells

A study undertaken by biologists at the University of California, Berkeley, has found that damage to a cell's DNA sets off a chain reaction that leads to the increased expression of a marker recognized by the body's immune system.

6 Jul 2005

Scientists solve structure of a critical innate immune system protein

Scientists at The Scripps Research Institute have solved the structure of a crucial human immune system molecule called TLR3, an acronym for Toll-like receptor three. In an upcoming issue of the journal Science, the protein is described as a large horseshoe-shaped coil composed of 23 leucine-rich repeats (LRRs).

27 Jun 2005

Molecule found in liver cells could explain a lot about the relationship between diet, lipid levels in blood, and atherosclerosis

A team of researchers at the University of Pennsylvania School of Medicine have made a discovery that a molecule found in liver cells is important in explaining the relationship between diet, lipid levels in blood, and atherosclerosis.

15 May 2005

Critical lock and key mechanism found for the assembly of tumor blood vessels

A critical lock and key mechanism that allows the final step in the completion of new blood vessel formation has been identified by a University of California, San Diego (UCSD) School of Medicine team in research that promises to lead to a new way to halt tumor growth by cutting off the tumor blood supply.

3 May 2005

Researchers set a new standard in the design and engineering of nuclear hormone receptor-based genetic on-off switches

Researchers at the University of Illinois at Urbana-Champaign have set a new standard in the design and engineering of nuclear hormone receptor-based genetic on-off switches, without causing new problems or aggravating existing ones.

7 Apr 2005

Genomics and proteomics to increase the efficiency of drug discovery and development

While the United Sates is still the world leader, Europe is having a good deal of success in the field of advanced genomics and proteomics research. Significant government funding together with the presence of large pharmaceutical companies has made Europe a major competitor in the efforts to deploy genomics and proteomics as vital tools in drug discovery and development.

5 Apr 2005

Structure of key protein in innate immune response

In a report published in the Journal of Biological Chemistry, scientists in Korea announced their elucidation of three-dimensional structure of CD14 and showed how it is perfectly suited to bind to certain bacterial products.

21 Mar 2005

Why estrogenic hormones produce unintended results in women

New research is shedding light on why estrogenic hormones produce unintended results in women, giving hope to the idea that new drugs might reach their targets and work more effectively. Ultimately it could mean that postmenopausal women would know that hormone-replacement therapy would have only its intended result.

13 Feb 2005

$Phenoxodiol gets fast track status for its intended use in patients with hormone-refractory prostate cancer$

Phenoxodiol gets fast track status for its intended use in patients with hormone-refractory prostate cancer

Marshall Edwards today announced that the U.S. Food and Drug Administration (FDA) has granted the investigational anti-cancer drug, phenoxodiol, fast track status for its intended use in patients with hormone- refractory prostate cancer (HRPC).

26 Jan 2005

Ubiquitination protects against improper Notch signaling

The Notch pathway is an important molecular signaling mechanism whose existence has been known, or at least hinted at, for nearly a century since the identification of a mutant strain of Drosophila fruit flies with "notched" wings in Thomas Hunt Morgan's lab in 1910.

28 Dec 2004

Blocking a key molecule protects breast implants, permanent catheters, pacemakers and artificial joints from rejection and damage by the body

Blocking a key molecule protects breast implants, permanent catheters, pacemakers, artificial joints, glucose sensors for diabetics, and other biomaterials from rejection and damage by the body, according to a study published this month in The American Journal of Pathology.

20 Dec 2004

Wide angle X-ray scattering (WAXS) could help produce lead drugs for disease therapy

Structural changes in proteins can now be seen in increased detail, using a new application of an existing technique. The application, developed at the U.S. Department of Energy's Argonne National Laboratory, could help produce lead drugs for disease therapy.

8 Dec 2004

Fossil record of the human immune system reveals antibodies that block cancer metastasis

A team of researchers at The Scripps Research Institute has reconstructed the "fossil record" of the immune systems of a group of human cancer patients to investigate if they had ever produced antibodies against their disease.

4 Dec 2004

Cancer Research Technology grants AstraZeneca an exclusive license to a key patent

Cancer Research Technology Limited has announced that AstraZeneca has licensed exclusive worldwide rights to a patent family relating to a nuclear receptor/co-activator binding motif.

1 Dec 2004

Concord grapes increase good cholesterol

Drinking Concord grape juice significantly increased HDL--the good cholesterol--and significantly lowered two markers of inflammation in people with stable coronary artery disease, according to results of a study presented in the November issue of the journal Arteriosclerosis, Thrombosis and Vascular Biology.

16 Nov 2004

FDA fast tracks investigational anti-cancer drug, phenoxodiol

Marshall Edwards today announced that the U.S. Food and Drug Administration (FDA) has granted the investigational anti-cancer drug, phenoxodiol, Fast Track status for its intended use in patients with recurrent ovarian cancer.

4 Nov 2004

Stress response proteins offer a promising target for a novel drug guidance system

Their study, published in the September issue of the journal Cancer Cell, demonstrates how researchers can find protein tags that are unique to cancer cells and then tweak a drug delivery system to zero in on those tags and destroy the cells.

21 Sep 2004

New anti-inflammatory strategy for cancer therapy

A new strategy for cancer therapy, which converts the tumor-promoting effect of the immune system’s inflammatory response into a cancer-killing outcome, is suggested in research findings by investigators at the University of California, San Diego (UCSD) School of Medicine.

20 Sep 2004

Phase 1 clinical trial of new anticancer drug from Human Genome Sciences

Human Genome Sciences has begun dosing patients in a Phase 1 clinical trial of HGS-TR2J, a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.

25 Aug 2004

Self-recovery from Hep C infection linked to genes that suppress action of killer immune cells

In a study to be published in Science online Aug. 6, researchers at Johns Hopkins have found that genes involved in suppressing the body's defensive "killer" immune cells are a potential key factor in spontaneous recovery from hepatitis C.

5 Aug 2004